Direct effects of canagliflozin on human myocardial redox signalling: a novel role for SGLT1 inhibition
Kondo H, Akoumianakis I, Akawi N, Kotanidis C, Antonopoulos A, Carena M, Badi I, Oikonomou E, Reus E, Krasopoulos G, Chuaiphichai S, Shirodaria C, Channon K, Casadei B, Antoniades C. Direct effects of canagliflozin on human myocardial redox signalling: a novel role for SGLT1 inhibition. European Heart Journal 2020, 41: ehaa946.3351. DOI: 10.1093/ehjci/ehaa946.3351.Peer-Reviewed Original ResearchHuman primary cardiomyocytesNitric oxide synthaseMyocardial biopsiesHuman myocardial biopsiesMyocardial redoxOxide synthaseHuman myocardiumSodium-glucose cotransporter 2 inhibitorsMyocardial NADPH oxidase activityRight atrial appendage biopsiesGlucose cotransporter 2 inhibitorsUncoupled nitric oxide synthaseSGLT1/SGLT2 inhibitorsCotransporter 2 inhibitorsEffects of canagliflozinHeart failure patientsPro-fibrotic markersRecent clinical trialsBritish Heart FoundationNADPH oxidase subunitsBioavailability of tetrahydrobiopterinNADPH oxidase activityAnti-apoptotic effectsDirect effectBasal O2